October 2026—This discussion is part of a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with vendors and laboratory experts to spotlight a company and a customer for their laboratory solutions and work. He spoke on September 30, 2026 with John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, Flora Berisha, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson, Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering, Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering, Cancer Center
- Four Voices, One Conversation: leaders from AstraZeneca, Johnson & Johnson, and two Memorial Sloan Kettering physicians come together to bring biopharma, molecular pathology, and treating oncology in one room
- Assessing the Impact of Delayed Molecular Testing: Panelists weigh in on missed trial windows, repeat biopsies, and first-line decisions made on incomplete information
Improving the Precision Medicine Ecosystem: Panelists discuss what has to be true for testing to move closer to the patient — infrastructure, validation and economics — and what each stakeholder stands to gain - Locating Where Time Is Lost: From specimen handling to staffing, panelists work through the pipeline bottlenecks that clinicians and sponsors rarely see, and which of them are structural rather than technical
Coordinating for a Better Future: Each panelist names one practical action the field should take over the next 12–24 months to move rapid, high-quality molecular testing from exception to standard of care
This roundtable discussion is sponsored by Pillar Biosciences. CAP TODAY does not endorse named products in commercial roundtables, and the publisher’s comments are his own and not necessarily reflective of CAP TODAY or College of American Pathologists policy.